Journal of Oncology / 2019 / Article / Tab 4

Research Article

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?

Table 4

Impact of the AR/ER, AR/PgR, and ER/PgR ratios, assessed on primary tumors, on OS in the overall series (no. 159).

Median ratios (range)

AR/ER0.95 (0 - 95)

AR/PgR1.59 (0 - 100)

ER/PgR1.35 (0 - 100)

OS according to best cut-off ratio
 Median follow-up: 78 months (range 3-155)

no. deaths/no. patientsMedian OS (months)
(95% CI)
HR (95% CI)p

Overall63/10462 (50-71)--

AR/ER

<1.3053/8863 (50 - 76)1.00

≥1.3010/1652 (23 - NR)1.10 (0.56 - 2.16)0.792

AR/PgR

<1.7031/5166 (53 - 84)1.00

≥1.7032/5346 (36 - 65)1.45 (0.88 - 2.39)0.147

ER/PgR

<2.0027/4981 (62 - 88)1.00

≥2.0036/5546 (36 - 60)1.90 (1.14 - 3.17)0.014

AR, androgen receptor; ER, estrogen receptor; PgR, progesterone receptor; OS, overall survival: HR, hazard ratio; CI, confidence interval; ND, not determinable; NR, not reached.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.